Advances in CLL/SLL: Focus on Bruton’s Tyrosine Kinase Inhibitors
In-Person and Livestreamed
This is an ancillary event being held during the 2022 ASCO Annual Meeting
Not an official event of the 2022 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer® the ASCO Foundation.
June 6, 2022
Dinner: 7:00pm - 7:30pm CT
Program: 7:30pm - 9:00pm CT
1.5 CME/CNE/CPE/AAPA/AANP Credits
Susan M. O'Brien, MD
Professor of Medicine
Division of Hematology/Oncology
University of California, Irvine
Provided by HMP Education, an HMP Global Company.
For questions regarding this educational activity, please call 609-371-1137 or email firstname.lastname@example.org.
This activity is designed for oncology healthcare professionals, including physicians, nurses, pharmacists, and other members of the multidisciplinary oncology care team, particularly those who care for patients with CLL/SLL.
After participating in this activity, learners should be better able to:
- Evaluate the most recent clinical efficacy, safety, and long-term patient outcomes data for combination fixed-duration treatments with BTK inhibitors and other targeted drugs for the treatment of CLL/SLL
- Incorporate guideline recommendations for the treatment of patients with CLL/SLL into clinical practice
- Describe factors that influence therapeutic sequencing in the treatment of CLL/SLL
- Anticipate common adverse events associated with BTK therapies and combinations when treating patients with CLL/SLL
- Implement management strategies for adverse events when treating patients with CLL/SLL
To be eligible for credit, participants must complete the online activity and the evaluation. Upon completing the activity, there will be instructions on how to complete the evaluation and print a certificate or other documentation of credit.
Release Date: June 6, 2022
Expiration Date: August 6, 2022
Estimated Time to Complete: 1.5 hours
There is no fee associated with this activity.
In support of improving patient care, HMP Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
HMP Education designates this internet live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This continuing nursing education internet live activity awards 1.5 contact hours.
Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.5 contact hours.
American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 CreditTM from organizations accredited by the ACCME.
This internet live, knowledge-based activity has been approved for a maximum of 1.5 contact hours (.015 CEUs).
The certificate is not the official record of your participation in the activity. The official record of credit will be the information in the CPE Monitor system. Following ACPE Policy, HMP Education must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity. HMP Education is not able to report your claimed credit after this 60-day period. Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended.
HMP Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet live/enduring activity is designated for 1.5 AAPA Category 1 credits. PAs should only claim credit commensurate with the extent of their participation.
USE OF PROPRIETARY NAMES
This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.
UNAPPROVED AND/OR INVESTIGATIONAL USES OF DRUGS AND DEVICES
This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of HMP Education.
The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.
Neither HMP Education nor any of its subsidiaries or affiliates is affiliated with, or formally endorsed by a medical society.
The opinions expressed in this educational activity are those of the faculty and are not attributable to HMP Education or HMP. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
HMP Education is an independent provider of continuing medical education. HMP Education has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.
In accordance with our disclosure policies, HMP Education is committed to ensuring balance, independence, objectivity, and scientific rigor for all accredited continuing education. These policies include assigning relevance to, and mitigating, all perceived or real conflicts of interest between any individual with control over the content and any ineligible company (commercial interest) as defined by the ACCME.
Any individual with control over accredited content, including planner, faculty, and reviewer, is required to globally disclose:
- Individual relationship(s) or lack thereof, and its nature, with any/all ineligible company, and;
- Any investigational, off-label, or non-FDA approved content or discussion
HMP Education has reviewed these disclosures, assigned relevance based on the relationship and scope of content, and identified those with the potential to compromise the goals and educational integrity of the education. Relevant relationships, or lack thereof, are shared with the learner.
Education has been independently peer-reviewed to validate content, mitigate identified conflicts of interest, and ensure:
- All recommendations involving clinical medicine is based on evidence that is accepted within the medical profession as adequate justification for their indications and contraindications in the care of patients.
- All scientific research referred to, reported, or used in accredited continuing education in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection, and analysis.
- Content is appropriate, fair and balanced, unbiased, referenced, and non-promotional.
The faculty has reported the following:
Dr. O'Brien: Consultant – AbbVie, Alexion, Amgen, Aptose Biosciences Inc., Astellas, AstraZeneca, Autolus, Bristol Myers Squibb, Celgene, DynaMed, Eli Lilly and Company, Gilead, GlaxoSmithKline, Janssen Oncology, Johnson and Johnson, Juno Therapeutics, MEI Pharma, Inc., Merck, NOVA Research Compan, Pfizer, Pharmacyclics, TG Therapeutics, Vaniam Group LLC, Verastem, Vida Ventures; Research Support – Acerta, Alliance, Beigene, Ltd., Caribou Biosciences, Inc., Gilead, Kite, Loxo Oncology, Inc., Mustang, Nurix Therapeutics, Inc. Pfizer, Pharmacyclics, Regeneron, TG Therapeutics;
Susie Seaman, NP, MSN, CWOCN (nurse planner)
Susie Seaman Wound Care Consulting
San Diego, California
Ms. Seaman has disclosed no relevant financial relationship with any ineligible company (commercial interest).
HMP Education planners and staff include Samantha Conforti, Lacey Schmeidler, Randy Robbin, and Andrea Zimmerman.
No HMP Education planner or staff has disclosed a relevant financial relationship with any ineligible company (commercial interest).
HMP Education complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call 609-371-1137.
HMP Education protects the privacy of personal and other information regarding participants, educational partners, and joint providers. HMP Education and our joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. HMP Education maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.
Any participant wanting to file a grievance with respect to any aspect of a continuing education activity accredited by HMP Education may contact Samantha Conforti, Senior Manager, Accreditation and Compliance, by phone at 609-371-1137, by email at email@example.com or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. Ms. Conforti will review the grievance and respond within 30 days of receiving the complaint.
Supported by independent educational grants from BeiGene and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.